Johnson & Johnson lists Cavanaugh stock awards
Cavanaugh reports owning 71 J&J shares directly and 428 indirectly via a 401(k), tied to RSUs that convert one-for-one as they vest.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
JOHNSON & JOHNSON (JNJ) has an initial insider ownership report from Thomas Cavanaugh, EVP WW Chair, Innovative Med. The filing lists existing equity awards and stock holdings rather than new transactions. Reported positions include several employee stock option grants on common stock, with exercise prices ranging from $151.41 to $243.45 per share and expiration dates between 2030 and 2036, plus multiple tranches of restricted share units that convert into common stock on a one-for-one basis as they vest. Cavanaugh also reports direct ownership of 71 Johnson & Johnson common shares and 428 shares held indirectly through a 401(k) plan.
Insider Trade Summary
12 transactions reported
Mixed
12 txns
Insider
Cavanaugh Thomas
Role
EVP WW Chair, Innovative Med.
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Employee Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Employee Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Employee Stock Options (Right to Buy) F2 | -- | -- | -- |
| holding | Employee Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Employee Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Employee Stock Options (Right to Buy) F3 | -- | -- | -- |
| holding | Restricted Share Units F4 | -- | -- | -- |
| holding | Restricted Share Units F5 | -- | -- | -- |
| holding | Restricted Share Units F6 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock F1 | -- | -- | -- |
Holdings After Transaction:
Employee Stock Options (Right to Buy) — 122,556 contracts (Direct);
Restricted Share Units — 5,337 contracts (Direct);
Common Stock — 71 shares (Direct);
Common Stock — 428 shares (Indirect, By 401k)
Footnotes (6)
- F1. Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund under the Johnson & Johnson Savings Plan as of the Plan's most recent reporting date (7/31/2026).
- F2. Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests in three equal annual installments beginning on the first anniversary of the grant date.
- F3. Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests and is exercisable on the third anniversary of the grant date.
- F4. Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
- F5. Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2025 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
- F6. Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2024 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
Key Figures
Direct common shares held: 71 shares
Indirect common shares via 401(k): 428 shares
Option exercise price: $243.45 per share
+5 more
8 metrics
Direct common shares held
71 shares
Common Stock, direct ownership as of 2026-09-01
Indirect common shares via 401(k)
428 shares
Common Stock held indirectly "By 401k" as of plan date 2026-07-31
Option exercise price
$243.45 per share
Employee Stock Options (Right to Buy), expiration 2036-02-15, 15,839 underlying shares
Option exercise price
$156.15 per share
Employee Stock Options (Right to Buy), expiration 2035-02-15, 25,493 underlying shares
Option exercise price
$151.41 per share
Employee Stock Options (Right to Buy), expiration 2030-02-10, 16,543 underlying shares
RSU underlying shares
2,275 shares
Restricted Share Units granted 2026-02-15, vest in three equal annual installments
RSU underlying shares
2,097 shares
Restricted Share Units granted 2025-02-15, vest in three equal annual installments
RSU underlying shares
965 shares
Restricted Share Units granted 2024-02-15, vest in three equal annual installments
Key Terms
Employee Stock Options (Right to Buy), Restricted Share Units, Long-Term Incentive Plan, dividend reinvestment, +1 more
5 terms
Employee Stock Options (Right to Buy) financial
"security_title "Employee Stock Options (Right to Buy)" with underlying Common Stock"
Long-Term Incentive Plan financial
"Awarded under Issuer's Long-Term Incentive Plan. The Stock Option Award vests"
A long-term incentive plan is a company program that pays executives or employees with stock, options, or cash tied to multi-year performance goals, where the rewards become theirs only after meeting conditions over time. Think of it as a delayed bonus or retirement-style reward that aligns employees’ interests with shareholders by encouraging them to boost long-term value; investors watch these plans because they affect pay costs, share dilution and management incentives.
dividend reinvestment financial
"Includes shares accrued due to dividend reinvestment in the Johnson & Johnson Stock Fund"
Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.
beneficial ownership financial
"Form 3 is an initial statement of beneficial ownership of securities"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 3 filing for JNJ by Thomas Cavanaugh disclose?
The Form 3 discloses Thomas Cavanaugh’s initial beneficial ownership in Johnson & Johnson, including employee stock options, restricted share units, and direct and 401(k) holdings of common stock. It records existing positions and does not report any new purchases or sales.
What employee stock options are reported in the JNJ Form 3 for Thomas Cavanaugh?
The filing lists multiple employee stock option awards on Johnson & Johnson common stock with exercise prices between $151.41 and $243.45 per share and expiration dates from February 10, 2030 to February 15, 2036, each granted under the company’s Long-Term Incentive Plan.
Are there any buy or sell transactions in this JNJ Form 3?
No. The Form 3 for Johnson & Johnson shows holding entries only. The transaction summary records no buys, sells, exercises, or gifts, indicating that the filing is limited to disclosing existing equity awards and stock positions as of the reporting date.
How do Thomas Cavanaugh’s JNJ stock options vest according to the filing?
Some stock option awards vest in three equal annual installments beginning on the first anniversary of the grant date, while others vest and become exercisable on the third anniversary of the grant date, all under Johnson & Johnson’s Long-Term Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
